Abstract library

46 results for "thoracic".
#1142 GastroEnteroPancreatic and Thoracic Neuroendocrine Tumors and the Ectopic Adrenocorticotropin Syndrome
Introduction: Ectopic Adrenocorticotropin (ACTH) Syndrome (EAS) is associated with a variety of malignancies, predominantly of neuroendocrine origin. Several series report on the relative contribution of EAS in the spectrum of Cushing’s syndrome. However, information on the incidence/prevalence and prognosis of EAS in the setting of patients diagnosed with Thoracic or GEP-NETs is virtually absent.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: drs. Kimberly Kamp
#467 Thoracic and Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) and Ectopic Adrenocorticotropin (ACTH) Syndrome (EAS)
Introduction: Ectopic Adrenocorticotropin (ACTH) Syndrome (EAS) is associated with a variety of malignancies, mostly of neuroendocrine origin. Several series report on the relative contribution of EAS in the spectrum of Cushing’s syndrome. However, information on the incidence/prevalence of EAS in the setting of patients diagnosed with thoracic or gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) is virtually absent.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Drs. Kimberly Kamp
Keywords: ACTH, GEP-NETS, Cushing
#484 Diagnostic Accuracy of Gallium-68 Somatostatin Receptor Positron Emission Tomography in Patients with Thoracic and Gastroenteropancreatic Neuroendocrine Tumors: A Meta-Analysis
Introduction: Gallium-68 somatostatin receptor (SMSR) positron emission tomography (PET) is a valuable diagnostic tool for patients with neuroendocrine tumors (NET). To date, a meta-analysis about the diagnostic accuracy of this functional imaging method is lacking.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Giorgio Treglia
#1797 An Open-Label Phase II Study to Evaluate the Efficacy and Safety Of PDR001 in Patients with Advanced Well-Differentiated Non-Functional NET of Pancreatic, Gastrointestinal (GI), or Thoracic Origin Who Have Progressed on Prior Treatment
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti-PD-1 and anti-PD-L1, have become established treatment (tx) options in various solid tumors. However, there is a paucity of data on checkpoint inhibitors in NET. In a phase I trial of PDR001 (mAb checkpoint inhibitor targeting PD-1) conducted in patients (pts) with multiple solid tumor types, a pt with histologically confirmed metastatic atypical pulmonary carcinoid demonstrated a RECIST-based tumor response and clinical benefit.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: James C Yao
Authors: Yao J C, Fazio N, Pavel M, Strosberg J, ...
Keywords: PDR001, immunotherapy, NET
#2071 ElevatION:NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Anamika Gulati
Authors: Yao J C, Fazio N, Li D, Pavel M, ...
Keywords: PDR001, immunotherapy, NET
#54 The clinical challenge of patients with a thoracic or neck neuroendocrine tumor: a retrospective analysis from a single Irish institution
Introduction: Thoracic and neck neuroendocrine tumors (T-N-NETs) represent a rare and intriguing condition and the management of patients with a NET localized at the thorax or neck can be extremely problematic. An expert and multidisciplinary approach is generally required for the optimal management of NET patients. A systematic multidisciplinary approach to NET patients has been recently established at our institution.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Gianluca Tamagno
#667 Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors after Treatment with [177Lu-DOTA0,Tyr3]Octreotate
Introduction: Response Evaluation Criteria in Solid Tumors (RECIST) (unidimensional), Southwest Oncology Group (SWOG) solid tumor response criteria (bidimensional), and their modified variants (mRECIST/mSWOG) are used to assess treatment response in gastroenteropancreatic and thoracic neuroendocrine tumors (NETs).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Esther I Van Vliet
#512 Epidemiology of Neuroendocrine Tumors in France: The PRONET Study
Introduction: Because of recent progress in neuroendocrine tumor treatment (NET), more data are required about this pathology in France.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Xavier Parot
#2054 Mediastinal Paraganglioma - A Challenge from the Surgical Point of View
Introduction: Mediastinal paraganglima are extremely rare neuroendocrine tumors.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Katarzyna Blazejczyk
Authors: Blazejczyk K, Leschber G, ...
#2194 Therapeutic Sequences in Patients with G1-G2 Neuroendocrine Tumors (NETs): An Observational, Multicentre, Prospective/Retrospective Study
Introduction: Many different therapies are suggested by guidelines to treat loco-regionally advanced or metastatic G1-G2 neuroendocrine tumors (NETs). However, a precise therapeutic algorithm has not yet been established.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD, PhD Antongiulio Faggiano